CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I-II Study of Ruxolitinib (INCB18424) for Patients With Chronic Myeloid Leukemia (CML) With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01751425
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:44.475133+00:00
Published At: 2025-06-03T00:00:00+00:00
Record Updated At: 2025-06-03
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission", "Minimal Residual Disease", "Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-06-03"
protocolSection.identificationModule.nctId: "NCT01751425"
protocolSection.identificationModule.officialTitle: "Phase I-II Study of Ruxolitinib (INCB18424) for Patients With Chronic Myeloid Leukemia (CML) With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.